A.P. Pharma Reports Results for the First Quarter 2007
Highlights -- APF530 Development: -- Patient enrollment rates remain steady and lead to an NDA filing in 2008 -- Held successful Clinical Investigators meeting -- Filed an S-1 registration statement to raise additional capital of up to $28.8 million. -- Cash, cash equivalents and marketable securities $9.4 million at March 31.
Results of Operations
In this news release, the "Company", "we", "us", and "our" refer to A.P. Pharma, Inc.
We have generated no revenue since the fourth quarter of 2005, when we sold our rights to receive royalties on certain former products. Accordingly, our total operating expenses of $6.1 million this quarter vs. $4.4 million in the first quarter of 2006 are directly reflected as operating losses. Our research and development ("R&D") expenses increased by 44%, from $3.5 million to $5.0 million, reflecting higher costs associated with our pivotal Phase 3 trial for APF530, which we began in the second quarter of 2006. In the first quarter of 2006, our R&D expense reflected costs associated with our lower cost Phase 2 study for APF530. Our general and administrative expenses increased by 20% to $1.1 million, primarily due to legal expenses associated with our current fund raising activities. In total, our operating loss widened by $1.7 million to $6.1 million from $4.4 million.
Following interest income of $148,000 and certain smaller items below our operating loss line which netted to a charge against income of $44,000, we reported a net loss of $6.0 million or 24 cents per share. In last year's first quarter, we recorded a gain of $23.4 million on the sale of our rights to receive royalties on former products. As a result, we reported net income of $19.3 million or 76 cents per share. (All references to per share are to diluted amounts)
In December we announced that because of the extended timeline for patient enrollment, we now expect to file the New Drug Application (NDA) for APF530 in 2008, assuming successful completion of our financing plans. Currently APF530 is in pivotal Phase 3 clinical trials, with more than 80% of the planned 80 clinical sites for the trial now active, following the closure of several previously established sites that were deemed nonproductive. Patient enrollment in the trial continues at a steady pace. We recently completed a clinical investigators' meeting to address the complexity of our study and to stimulate patient enrollment. Over 80% of the sites were represented. We believe that one of the outcomes of this meeting will be enhanced involvement and enthusiasm of participating centers, which will lead to improved patient enrollment rates.
On April 5, 2007, we filed with the Securities and Exchange Commission (the "SEC") a registration statement on Form S-1 for a proposed public offering of up to $28.8 million of our common stock. We plan to use the proceeds from this offering to complete the clinical development of APF530, the development and clinical testing of other product candidates, and for working capital, capital expenditures and general corporate purposes.
Our lead product candidate using our proprietary Biochronomer(TM) technology is APF530, which contains granisetron, a drug approved for the prevention of chemotherapy-induced nausea and vomiting, or CINV. We selected granisetron because it is a potent drug which blocks a specific receptor found in the gut that is responsible for triggering CINV. Additionally, the applicable granisetron patent will expire in the United States on December 29, 2007. APF530 is designed to provide at least five days prevention of CINV. In September 2005, we completed a Phase 2 human clinical trial of APF530 that achieved all of its primary and secondary endpoints. In May 2006, we initiated our pivotal Phase 3 clinical trial of AFP530. We believe that this clinical trial will lead to regulatory approval of APF530 for the prevention of acute and delayed onset CINV for patients undergoing both moderately and highly emetogenic, or vomit-inducing, chemotherapy.
Our pivotal Phase 3 clinical trial, initiated in May 2006, is a multicenter, randomized, observer-blind, actively-controlled, double-dummy, parallel group study that will compare the efficacy of APF530 with Aloxi(R). The trial will include approximately 1,350 patients, stratified in two groups, one receiving moderately and the other receiving highly emetogenic chemotherapeutic agents. In each group, the patients are randomized to receive in the first chemotherapy treatment cycle either APF530 high dose (10 mg), APF530 low dose (5 mg) or the currently approved dose of Aloxi. In subsequent treatment cycles (up to three additional cycles), the patients are re-randomized to either of the two APF530 doses.
We commissioned Timely Data Resources, Inc., or TDR, to conduct market research to determine oncologists' and oncology nurses' perceptions of current antiemetics for CINV. This survey, completed in August 2006, was intended to assess the market opportunity for APF530 for the prevention of CINV. TDR interviewed 75 randomly selected medical oncologists and 25 oncology nurses from across the United States. The survey concluded that there is significant unmet need in the treatment of CINV, especially delayed onset CINV. 84% of the surveyed oncologists and oncology nurses currently use Aloxi and continue to have patients who experience CINV, particularly delayed onset CINV.
Management will host an investment-community conference call today beginning at 11:00 a.m. Eastern time (8:00 a.m. Pacific time) to discuss the financial results, to provide a business update and to answer questions.
To participate in the live call by telephone, please dial (888) 803-8275 from the U.S. or (706) 634-1287 from outside the U.S. A telephone replay will be available for 48 hours by dialing (800) 642-1687 from the U.S. or (706) 645-9291 from outside the U.S., and entering reservation number 6645110. The call will also be broadcast live on A.P. Pharma's website, www.appharma.com. A replay will be available for 30 days.
About A.P. Pharma
We are a specialty pharmaceutical company focused on developing pharmaceutical products using our proprietary Biochronomer polymer-based drug delivery technology. Our product development philosophy is based on incorporating approved therapeutics into our proprietary bioerodible drug delivery technology to create controlled release pharmaceuticals to improve treatments for diseases or conditions. Our lead product candidate, APF530, is currently in a pivotal Phase 3 clinical trial for the prevention of acute and delayed onset chemotherapy-induced nausea and vomiting, or CINV. We expect to complete enrollment of our pivotal Phase 3 clinical trial in the first half of 2008 and to announce results of that trial in the third quarter of 2008. We expect to file our new drug application, or NDA, for approval of APF530 in the fourth quarter of 2008.
Our primary focus is to advance our proprietary Biochronomer technology, consisting of bioerodible polymers designed to release drugs over a defined period. We have completed over 100 in vivo and in vitro studies demonstrating that our Biochronomer technology is potentially applicable to a range of therapeutic areas, including pain management, prevention of nausea and vomiting, control of inflammation and treatment of ophthalmic diseases. We have also completed comprehensive animal and human toxicology studies that have established that our Biochronomer polymers are safe and well tolerated. Furthermore, our Biochronomer technology can be designed to deliver drugs over periods varying from days to several months.
This news release contains "forward-looking statements" as defined by the Private Securities Reform Act of 1995. These forward-looking statements involve risks and uncertainties including uncertainties associated with timely development, approval, launch and acceptance of new products, satisfactory completion of clinical studies, establishment of new corporate alliances, progress in research and development programs and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law.
A.P. PHARMA, INC. Statement of Operations Highlights (in thousands, except per share data) (Unaudited) Three Months Ended March 31, March 31, 2007 2006 --------- --------- Revenue $ 0 $ 0 Operating Expenses: Research & Development 4,987 3,469 General & Administrative 1,118 932 ------- ------- Total Operating Expenses 6,105 4,401 ------- ------- Operating Loss (6,105) (4,401) Interest Income, Net 148 262 Gain on Sale of Interest in Royalties 0 23,421 Other Income, Net 0 10 --------- ------- Income (Loss) from Continuing Operations (5,957) 19,292 Loss from Discontinued Operations (24) 0 Gain on Disposition of Discontinued Operations 16 7 ------- --------- Income (Loss) before Income Taxes (5,965) 19,299 Tax Provision 36 0 ------- --------- Net Income (Loss) $(6,001) $19,299 ========= ========= Diluted Earnings (Loss) Per Common Share: Income (Loss) from Continuing Operations $ (0.24) $ 0.76 ========= ========= Net Income (Loss) $ (0.24) $ 0.76 ========= ========= Shares used in Calculating Diluted Earnings (Loss) Per Share: 25,324 25,483 ======= =======
A.P. PHARMA, INC. Balance Sheet Highlights (in thousands) December March 31, 31, 2007 2006 (Unaudited) (1) ----------- -------- Assets Cash, Cash Equivalents and Marketable Securities $ 9,362 $15,522 Accounts Receivable, Net 125 75 Other Current Assets 522 609 ------- ------- Total Current Assets 10,009 16,206 Property and Equipment, Net 883 958 Other Non-Current Assets 70 87 Total Assets $10,962 $17,251 =========== ======== Liabilities and Stockholders' Equity Total Liabilities $ 4,735 $ 5,192 Stockholders' Equity 6,227 12,059 ------- ------- Total Liabilities and Stockholders' Equity $10,962 $17,251 =========== ========
(1) Derived from our audited financial statements for the year ended December 31, 2006 included in the Company's 2006 Annual Report on Form 10-K filed with the Securities and Exchange Commission.
SOURCE: A.P. Pharma, Inc.A.P. Pharma, Inc.
Gregory Turnbull, President and Chief Executive Officer
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Zack Bryant, email@example.com
Don Markley, firstname.lastname@example.org
Bruce Voss, email@example.com